In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33 Acute Myeloid Leukemia - Wikidata - awgldk - TriplyDB

In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33 Acute Myeloid Leukemia

In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33 Acute Myeloid Leukemia

http://www.wikidata.org/entity/Q35681332

about

P1343

Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia Re-evaluation of various molecular targets located on CD34+CD38-Lin- leukemia stem cells and other cell subsets in pediatric acute myeloid leukemia.From the mouse cage to human therapy: a personal perspective of the emergence of T-bodies/chimeric antigen receptor T cells.Chimeric antigen receptor T cell therapy in AML: How close are we?Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia.Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells Seatbelts in CAR therapy: How Safe Are CARS?CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies.Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells Immunotherapy in pediatric malignancies: current status and future perspectives Chimeric antigen receptor--modified T cells: clinical translation in stem cell transplantation and beyond.High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity.Immunotherapy for pediatric leukemia."Model t" cells: a time-tested vehicle for gene therapy T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?Molecular therapeutic approaches for pediatric acute myeloid leukemia.Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen.Antibody therapy for acute myeloid leukaemia.Adoptive immunotherapy for cancer.Immunotherapy in acute myeloid leukemia.Hematopoietic stem cell transplantation and immunotherapy for pediatric acute myeloid leukemia: an open challenge.Update on antigen-specific immunotherapy of acute myeloid leukemia.Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?Recent advances in T-cell immunotherapy for haematological malignancies.From therapeutic antibodies to chimeric antigen receptors (CARs): making better CARs based on antigen-binding domain.Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts.Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT.Tumor immunology: multidisciplinary science driving basic and clinical advances.Advances in immunotherapy for pediatric acute myeloid leukemia.Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer.The role of CD33 as therapeutic target in acute myeloid leukemia.Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled?Redirection of T cells with a first fully humanized bispecific CD33–CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells Synthetic immunology: T-cell engineering and adoptive immunotherapy

P2860

Q93324954-624682F4-38BA-4FB7-AD05-CD70A4C7D280

P1343

Q26795540-BF5ACBE8-7474-47A2-8AFB-8ECB42A8DE94 Q28554677-37191D3A-D381-43B8-87B4-D71361A0435F Q33429957-6C51C1BA-E451-4559-9107-E68B329C6DF6 Q34240799-E0728F86-2A00-412A-947D-54978AF7BB8B Q34545962-F67C5849-D17D-444E-A067-EEF06FD7A6D0 Q35146288-5AC93294-EFF9-4488-920A-6826AB400941 Q35591409-DC97FAA5-153B-46A0-BC85-0479DB85B5AD Q35661999-B568C751-A9FB-4D65-9E3E-DAAF4E8A325D Q35818365-0871ACA3-5739-4C18-A071-034AFE535856 Q36279306-8D402E31-5412-4A54-BC46-14926F88D29B Q36386891-761A0608-2446-4EBE-8C1C-BA55C9767E91 Q36470354-38509E72-F980-4694-8759-743CDB2AEEA0 Q36691818-AF588864-E977-4E82-BD83-C3B86329F58E Q36845643-74C12D30-E011-4539-BE3A-F547C2853BE9 Q36957716-D1AE3545-0153-43A3-B06D-0E8B270F2719 Q36968163-08DAE55A-844A-4219-8384-96ED7844C787 Q37201423-DE2D22C2-B29C-496E-BC7A-6740FFE9F0BA Q37272020-52F5838F-2248-4EE6-B62F-9E5D8E170EA8 Q37587956-97AF7B7E-A644-48B7-862B-2458E5A129AD Q37643136-5416CDDA-203A-4FE9-BD5E-97484614EA54 Q38066860-D2AB7165-917F-4BAB-A3E8-247AD69456C9 Q38169814-38B2F19F-4175-499F-9427-2D0B24065935 Q38170496-DDBE4A85-E819-48D2-BDC9-BB6A02FF955F Q38171574-2B78AEE9-30CB-4340-85AE-6575262E3A77 Q38195065-FA1248DC-0654-4D88-9785-8928286D891D Q38432103-0E9803D8-862C-4403-8256-F9D7D98ED498 Q38700209-BDEAAA2E-15DF-4A07-96F3-529459CEA1F9 Q38789518-1C5BCBCE-D0BA-458B-953E-4D3438AFB13E Q38951943-43B53A79-EBD6-4752-BDA6-37844C6F2ED5 Q41085306-4971B1E4-4328-41B7-8EA4-A26DDBB662C3 Q41558781-9F2ABA92-B67F-43B9-BECE-E255E878B8AD Q41564670-08173DFB-BFD3-4702-AC91-D538858B20D7 Q41853258-4EEF69C0-5B70-4B99-91E4-1FB526BDA85E Q47930962-F7C82C86-876E-4B38-BC92-2C9108BF932B Q52846906-EF5A287C-3757-4088-B194-C1915F18007E Q53056603-CB2B87C0-2277-4819-A8D6-EBD7D385A2A6 Q55292778-515A4903-D565-40A6-A41D-3B9FAC2138F2 Q57320364-69443A15-00C1-4A59-9849-D653A953BBC0 Q57823195-2D6163CE-2205-46FE-A0D3-BE19B6ECB03C

P2860

In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33 Acute Myeloid Leukemia

http://www.wikidata.org/entity/Q35681332

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

In Vitro and In Vivo Antitumor ...... st CD33 Acute Myeloid Leukemia

@ast

In Vitro and In Vivo Antitumor ...... st CD33 Acute Myeloid Leukemia

@en

type

label

In Vitro and In Vivo Antitumor ...... st CD33 Acute Myeloid Leukemia

@ast

In Vitro and In Vivo Antitumor ...... st CD33 Acute Myeloid Leukemia

@en

prefLabel

In Vitro and In Vivo Antitumor ...... st CD33 Acute Myeloid Leukemia

@ast

In Vitro and In Vivo Antitumor ...... st CD33 Acute Myeloid Leukemia

@en

P1433

Q35681332-9845ABCA-45A0-4AA0-B63E-2B0F0C39C911

P1476

Q35681332-95FDCC66-7E69-4A6D-A2C6-4CA55E32B634

P2093

Q35681332-04D1D9C6-6967-4FF0-ACBB-27F31D83ABDC

Q35681332-41AB8CBE-C73A-4FE4-8FA4-3ECD259D34DB

Q35681332-422194E4-8E9F-4621-A79E-FAA49D7FCB56

Q35681332-4C4FEF90-3D7B-474A-8781-CD7A840413E0

Q35681332-863A166A-C7EC-46B2-9B40-96856B2FE853

Q35681332-9675DF9B-91A6-410A-9F4D-921A56F2C317

Q35681332-B839B944-4FF3-442E-A519-CFED8293EAD3

Q35681332-C762D130-1BD2-4D95-8227-F7CF8C7C34E7

Q35681332-DD8AD56A-DBB4-4568-8342-D36B5A99B7DD

Q35681332-F3B49C3B-CAD1-4F08-BF59-899FA580AC6E

P2860

Q35681332-01CD0402-A8E6-41BB-8D84-84843D695D2F

Q35681332-02888393-679A-4B4B-9F18-2E5E4EB11C09

Q35681332-0296AD91-ABFC-4AA5-887D-C3AB006230C4

Q35681332-2608280F-E99D-48B8-8E32-FC5F329949ED

Q35681332-32CEADDD-B3A4-43E6-B5B3-D97514DCC2F7

Q35681332-335DB1C7-8942-485F-90B9-F2430C1B3FAD

Q35681332-360713E7-AA0F-47F3-B396-91B58CDAE0B5

Q35681332-4DE6B5B0-BBB2-4DB8-AE0A-419E8DB75979

Q35681332-5033922D-0C93-4C8F-93AB-98CAE6663968

Q35681332-532D5A63-20A0-499F-8B29-B660876F583C

P304

Q35681332-04206B02-CF00-447D-BD9B-FCC6BFA0B7E1

P31

Q35681332-99CF7A32-43A8-4C0D-9806-80FD6E88AD9C

P356

Q35681332-E92CF851-FF83-491D-A306-73E03C52E442

P478

Q35681332-86BF60EB-2C38-4A1E-9428-EAF29A22B580

P50

Q35681332-B2B5214B-63BD-4698-A8F8-B8661DB9EBAB

P577

Q35681332-B1C831F7-6403-456A-AA58-7CA44C6212C9

P5875

Q35681332-355CAAF1-2C46-45A1-BECD-582F77C38699

P698

Q35681332-5C7E4171-F870-404C-8945-F97756BE2C7B

P921

Q35681332-E6831E49-1811-480A-A67C-F8CD6B3455BD

P932

Q35681332-7887A667-82C1-4F87-9D4D-6B20AF8E6AA1

P356

P1433

Advances in Hematology

P1476

In Vitro and In Vivo Antitumor ...... st CD33 Acute Myeloid Leukemia

@en

P2093

A Biondi

http://www.w3.org/2001/XMLSchema#string

A Dutour

http://www.w3.org/2001/XMLSchema#string

A Lawson

http://www.w3.org/2001/XMLSchema#string

E Biagi

http://www.w3.org/2001/XMLSchema#string

E Yvon

http://www.w3.org/2001/XMLSchema#string

H Finney

http://www.w3.org/2001/XMLSchema#string

I Pizzitola

http://www.w3.org/2001/XMLSchema#string

M Brenner

http://www.w3.org/2001/XMLSchema#string

R Rousseau

http://www.w3.org/2001/XMLSchema#string

S Valsesia-Wittmann

http://www.w3.org/2001/XMLSchema#string

P2860

Adoptive immunotherapy for cancer: building on success

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

Implications of the expression of myeloid markers on normal and leukemic stem cells.

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.

The ins and outs of EBV infection.

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells.

T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells.

CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.

Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.

P304

683065

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2012/683065

http://www.w3.org/2001/XMLSchema#string

P478

2012

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-01-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221772680

http://www.w3.org/2001/XMLSchema#string

P698

22272203

http://www.w3.org/2001/XMLSchema#string

P921

P932

3261457

http://www.w3.org/2001/XMLSchema#string